Lars Bruening, CEO, Bayer UK & Ireland
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Address: 208 Bath Road, Slough, Berkshire, SL1 3WE,United Kingdom
Tel: +44 1 753 534 655
Web: http://www.ucb.com/
A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.1 billion in 2009.
Main therapeutic areas:
Immunology
Cimzia® (certolizumab pegol) – Crohn’s disease& Rheumatoid arthritis
Xyzal® (levocetirizine) – Allergies
Zyrtec® (cetirizine) – Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII) – Respiratory disease
Central Nervous System
Vimpat® (lacosamide) – Epilepsy
Keppra® (levetiracetam) – Epilepsy
Neupro® (rotigotine) – Parkinson’s disease & Restless Legs Syndrome
Nootropil® (piracetam) – Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII) – Attention Deficit Hyperactivity Disorder (ADHD)
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed…
Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James…
Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse…
With a strong historic footprint in Edinburgh, Canon Medical Systems has based one of its global R&D centres in Scotland from where it develops software for its devices. Ken Sutherland,…
After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR…
Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and…
See our Cookie Privacy Policy Here
